According to the latest international recommendations from 20183, preferred way of predictive testing for advanced non-squamous non-small cell lung carcinomas (NSCLC) is multigene testing including EGFR, ALK, ROS1, BRAF, MET, HER2, KRAS, and RET. Very recently, Food and Drug Administration (FDA) and European Medicine Agency (EMA) have approved treatment for tumors harboring neurotrophic tyrosine receptor kinase (NTRK) gene fusions, as a first-line or subsequent-line of therapy4. Here, ROS1 is linked to non-small cell lung carcinoma.